Upper GI Bleed — Nonvariceal

Key Points

• Stabilize the patient before focusing on lesion-specific therapy.
• A normal early hemoglobin does not exclude severe acute hemorrhage.
• Use the Glasgow-Blatchford Score to identify very low-risk patients, but do not substitute it for clinical judgment.
• A restrictive red-cell transfusion strategy around 7 g/dL is appropriate for most patients, with individualized exceptions.
• Perform upper endoscopy within 24 hours after adequate resuscitation for hospitalized patients.
• Treat active ulcer bleeding and nonbleeding visible vessels endoscopically; do not use epinephrine injection alone as definitive hemostasis.
• After high-risk ulcer hemostasis, continue high-dose PPI therapy for 72 hours before transition to oral therapy.
• Recurrent bleeding usually merits repeat endoscopy before embolization or surgery.

Algorithm

1. Assess airway, breathing, circulation, mental status, and signs of ongoing hemorrhage; place monitoring and two reliable IV lines.
2. Obtain CBC, type and screen or crossmatch, metabolic panel, INR, and medication history; estimate pre-endoscopic risk.
3. Resuscitate with crystalloid and blood products as indicated; reverse clinically important anticoagulation in life-threatening bleeding.
4. Consider IV PPI and determine whether variceal bleeding remains plausible enough to add vasoactive therapy and antibiotics.
5. Arrange EGD within 24 hours after stabilization, sooner when ongoing severe bleeding requires urgent intervention.
6. Apply endoscopic hemostasis to high-risk stigmata using an accepted definitive modality, often in combination.
7. Continue post-hemostasis PPI, monitor for rebleeding, and address H. pylori, NSAIDs, antithrombotics, and the underlying lesion.
8. For recurrent or uncontrolled bleeding, repeat endoscopy and escalate to interventional radiology or surgery when needed.

Clinical Synopsis & Reasoning

Upper gastrointestinal bleeding should be suspected with hematemesis, coffee-ground emesis, melena, or hematochezia accompanied by hemodynamic instability. Initial assessment should establish severity before pursuing the exact lesion. Look for shock, orthostasis, syncope, ongoing hematemesis, altered mental status, cardiopulmonary disease, anticoagulant exposure, liver disease, NSAID use, prior ulcer disease, and previous GI bleeding. A normal initial hemoglobin does not exclude major acute blood loss because equilibration takes time. BUN may rise disproportionately to creatinine because of digestion and absorption of blood, but this finding is not diagnostic. The Glasgow-Blatchford Score is useful before endoscopy to identify very low-risk patients who may be candidates for outpatient management. A score of 0 to 1 is commonly used as the low-risk threshold when the clinical context is also reassuring. Distinguish likely nonvariceal bleeding from portal hypertensive bleeding because the latter requires vasoactive therapy and antibiotic prophylaxis. In a patient with cirrhosis or strong evidence of portal hypertension, treat initially as possible variceal bleeding until endoscopy clarifies the source. Endoscopy both diagnoses the lesion and determines rebleeding risk from stigmata such as active bleeding, a nonbleeding visible vessel, or an adherent clot. Consider alternative sources when the history is atypical, including epistaxis with swallowed blood, hemoptysis, aortoenteric fistula in patients with aortic grafts, and hemobilia after hepatobiliary intervention.

Treatment Strategy & Disposition

Resuscitate first. Place large-bore IV access, monitor closely, and give isotonic crystalloid while arranging blood products when clinically indicated. For most hospitalized adults with upper GI bleeding, use a restrictive red-cell transfusion threshold near 7 g/dL, while individualizing for active ischemia, profound ongoing hemorrhage, severe hypoxemia, or other special circumstances. Correct clinically important coagulopathy and reverse anticoagulants when bleeding is life threatening, balancing thrombosis risk. Give IV proton pump inhibitor therapy when ulcer bleeding is suspected, particularly after endoscopic hemostasis of a high-risk ulcer. The 2021 ACG guideline recommends endoscopy within 24 hours after presentation for hospitalized patients once resuscitation and stabilization are underway rather than pursuing routine emergent endoscopy before stabilization. Endoscopic treatment is indicated for active spurting or oozing and for a nonbleeding visible vessel; epinephrine injection should not be used as sole definitive therapy and is typically combined with a second modality. High-dose PPI therapy for 72 hours after successful hemostasis reduces rebleeding in high-risk ulcer disease, followed by oral PPI. Recurrent bleeding generally warrants repeat endoscopy before transcatheter arterial embolization or surgery. Test for Helicobacter pylori when peptic ulcer disease is identified and confirm eradication after treatment. Low-risk patients with reassuring vitals, adequate support, and a very low pre-endoscopic risk score may be discharged with prompt follow-up and outpatient management.

Epidemiology / Risk Factors

• Peptic ulcer disease remains a major cause of nonvariceal upper GI bleeding, with risk increased by H. pylori, NSAIDs, aspirin, and anticoagulants.
• Older age and cardiopulmonary, renal, or hepatic comorbidity increase adverse-event risk.
• Dieulafoy lesions, angioectasias, malignancy, erosive disease, and Mallory-Weiss tears are additional causes.
• Rebleeding risk is highest in lesions with active bleeding or a visible vessel.
• Medication reconciliation is essential because multiple antithrombotic agents and NSAIDs may contribute simultaneously.

Investigations

Endoscopic Stigmata and Therapy

Pharmacology

Prognosis / Complications

• Most nonvariceal bleeds can be controlled endoscopically, but mortality rises with shock, advanced age, comorbidity, and recurrent bleeding.
• Early rebleeding usually occurs within the first several days and is more likely with high-risk endoscopic stigmata.
• Repeat endoscopic therapy is effective for many recurrent ulcer bleeds and can avoid surgery.
• Long-term recurrence falls substantially when H. pylori is eradicated and unnecessary NSAID exposure is removed.
• Patients with cardiovascular disease may require earlier restart of antithrombotic therapy after hemostasis to limit thrombotic harm.

Patient Education / Counseling

• Avoid nonessential NSAIDs and discuss gastroprotection if antiplatelet or NSAID therapy must continue.
• Complete H. pylori treatment and obtain a test of eradication at the recommended interval.
• Seek emergency care for recurrent hematemesis, black stools with weakness or fainting, red blood with dizziness, or new chest pain or dyspnea.
• Review alcohol use and medication interactions that increase bleeding risk.
• Explain the plan for restarting aspirin or anticoagulation when relevant, because prolonged interruption can be dangerous.

Notes

The management target is durable hemostasis, not simply a higher hemoglobin. Excessive transfusion can increase volume burden and may worsen outcomes in some bleeding populations, which is why a restrictive strategy is preferred for most stable patients. Endoscopy timing should reflect resuscitation quality and ongoing bleeding rather than an automatic middle-of-the-night procedure in every case. Once bleeding is controlled, the long-term plan matters: eradicate H. pylori, stop unnecessary NSAIDs, use PPI protection when indicated, and coordinate safe resumption of antithrombotic therapy. A patient discharged after a low-risk presentation should have a clear medication plan, rapid follow-up, and explicit return precautions for recurrent bleeding or symptomatic anemia.

References

1. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding — Link
2. ACG Evidence Based GI: Upper GI Bleeding Timing — Link